Kazemi-Oula Golnesa, Ghafouri-Fard Soudeh, Mobasheri Maryam Beigom, Geranpayeh Lobat, Modarressi Mohammad Hossein
Department of Medical Genetics, Tehran University of Medical Sciences, Tehran, Iran ; Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Cell J. 2015 Fall;17(3):471-7. doi: 10.22074/cellj.2015.8. Epub 2015 Oct 7.
During the past decade, the importance of biomarker discovery has been highlighted in many aspects of cancer research. Biomarkers may have a role in early detection of cancer, prognosis and survival evaluation as well as drug response. Cancer-testis antigens (CTAs) have gained attention as cancer biomarkers because of their expression in a wide variety of tumors and restricted expression in testis. The aim of this study was to find putative biomarkers for breast cancer.
In this applied-descriptive study, the expression of 4 CTAs, namely acrosin binding protein (ACRBP), outer dense fiber 4 (ODF4), Rhox homeobox family member 2 (RHOXF2) and spermatogenesis associated 19 (SPATA19) were ana- lyzed at the transcript level in two breast cancer lines (MCF-7 and MDA-MB-231), 40 invasive ductal carcinoma samples and their adjacent normal tissues as well as 10 fibroadenoma samples by means of quantitative real-time reverse transcription polymerase chain reaction (RT-PCR).
All four genes were expressed in both cell lines. Expression of ODF4 and RH- OXF2 was detected in 62.5% and 60% of breast cancer tissues but in 22.5 and 17.5% of normal tissues examined respectively. The expression of both RHOXF2 and ODF4 was upregulated in cancerous tissues compared with their normal adjacent tissues by 3.31 and 2.96-fold respectively. The expression of both genes was correlated with HER2/neu overexpression. RHOXF2 expression but not ODF4 was correlated with higher stages of tumors. However, no significant association was seen between expression patterns and estrogen and progesterone receptors status.
ODF4 and RHOXF2 are proposed as putative breast cancer biomarkers at the transcript level. However, their expression at protein level should be evaluated in future studies.
在过去十年中,生物标志物的发现对于癌症研究的诸多方面都具有重要意义。生物标志物在癌症的早期检测、预后及生存评估以及药物反应中或许都发挥着作用。癌-睾丸抗原(CTAs)因其在多种肿瘤中表达且在睾丸中呈限制性表达,故而作为癌症生物标志物受到关注。本研究旨在寻找乳腺癌的潜在生物标志物。
在这项应用描述性研究中,采用定量实时逆转录聚合酶链反应(RT-PCR),在两种乳腺癌细胞系(MCF-7和MDA-MB-231)、40例浸润性导管癌样本及其相邻正常组织以及10例纤维腺瘤样本中,对4种CTAs,即顶体素结合蛋白(ACRBP)、外周致密纤维蛋白4(ODF4)、Rhox同源盒家族成员2(RHOXF2)和精子发生相关蛋白19(SPATA19)的转录水平进行分析。
所有4个基因在两种细胞系中均有表达。在乳腺癌组织中,ODF4和RHOXF2的表达分别在62.5%和60%的样本中被检测到,而在分别检测的正常组织中,其表达率为22.5%和17.5%。与相邻正常组织相比,癌组织中RHOXF2和ODF4的表达分别上调了3.31倍和2.96倍。这两个基因的表达均与HER2/neu过表达相关。RHOXF2的表达与肿瘤的更高分期相关,而ODF4则不然。然而,在表达模式与雌激素和孕激素受体状态之间未观察到显著关联。
ODF4和RHOXF2在转录水平被提议作为潜在的乳腺癌生物标志物。不过,它们在蛋白质水平的表达有待在未来研究中进一步评估。